Bisphosphonate drug holidays--when, why and for how long? (Q38617760)

4 September 2017

title

Bisphosphonate drug holidays--when, why and for how long? (English)

1 reference

4 September 2017

P Anagnostis

1 reference

4 September 2017

J C Stevenson

series ordinal

1 reference

4 September 2017

publication date

27 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

18 Suppl 2

1 reference

4 September 2017

page(s)

32-38

1 reference

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Benefits and risks of bisphosphonate therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

The cost-effectiveness of alendronate in the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Effect of osteoporosis treatment on mortality: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Increased risk for atypical fractures associated with bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Fracture risk remains reduced one year after discontinuation of risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Effect of stopping risedronate after long-term treatment on bone turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2015.1099092

10.3109/13697137.2015.1099092

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference